All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Eli Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Tafasitamab + rituximab + lenalidomide approved by Australia’s TGA for R/R FL
On April 23, 2026, Australia’s Therapeutic Goods Administration approved tafasitamab, a CD19 targeted monoclonal antibody, in combination with rituximab + lenalidomide for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL).1
Approval was based on results from the phase III inMIND (NCT04680052) study, evaluating tafasitamab + rituximab + lenalidomide vs placebo + rituximab + lenalidomide in patients with R/R FL.1,2 Patients receiving the tafasitamab combination had a longer median progression-free survival (PFS) compared with patients receiving the placebo combination (22.4 months vs 13.9 months; p < 0.0001).2 The best overall response rate was 84% with the addition of tafasitamab vs 72% without (p = 0.0014).2 The incidence of adverse events was similar between groups.2 A full analysis of overall survival is planned at 5 years of follow-up.2
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, what is the average vein-to-vein time when treating patients with DLBCL with a reimbursed CAR T-cell therapy (from apheresis to infusion)?
